Cetirizine
- Generic Name
- Cetirizine
- Brand Names
- Aller-tec, Aller-tec D, Quzyttir, Reactine, Wal Zyr 24 Hour Allergy, Wal Zyr D, Wal-zyr, Zerviate, Zyrtec, Zyrtec-D
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 83881-51-0
- Unique Ingredient Identifier
- YO7261ME24
- Background
Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , .
...
- Indication
Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes .
...
- Associated Conditions
- Allergy to Tree Pollen, Chronic Idiopathic Urticaria, Flu caused by Influenza, Perennial Allergic Rhinitis (PAR), Respiratory Allergy, Seasonal Allergic Rhinitis
- Associated Therapies
- -
Singapore's CBC and Mubadala acquired UCB's Chinese division for $680 million
CBC Group, Singapore's largest healthcare company, completed the acquisition of UCB's Chinese biopharmaceutical division for $680 million, in partnership with Mubadala Investment Company. The deal includes brands like UCB Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and a production site in Zhuhai. The new company, NeuroGen Pharma, aims to become the largest neurology company in China, leveraging CBC and Mubadala's innovations in neurosurgery.
Focuses on New Launch and Completes Divestment of Mature Product Business in China
UCB sold its mature neurology and allergy portfolio in China, including Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, and the Zhuhai manufacturing facility, to CBC Group and Mubadala Investment Company for $680 million. The portfolio will be transferred to NeuroGen Pharma, a new CNS-focused company. UCB also entered a commercialization agreement with Bioray to bring Bimzelx® to Chinese patients, shifting its strategy to focus on novel therapies.
Nicox Provides Third Quarter 2024 Update and First Half 2024 Financial Results
Nicox SA reports €19.7 million cash as of September 30, 2024, and expects to be financed into Q3 2025. Key milestones include the launch of ZERVIATE in China, Whistler Phase 3b trial results in Q1 2025, and Denali Phase 3 trial topline results in Q3 2025. The company is focusing on NCX 470 development and partnerships for commercialization.
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
Nicox and Soleus Capital sign a $16.5 million royalty and equity financing deal, including $15 million for VYZULTA royalties and $1.5 million in Nicox shares with warrants. The transaction aims to finance Nicox into Q3 2025, repay €5.2 million of debt, and accelerate the NCX 470 Denali Phase 3 trial, with topline results expected in Q3 2025.
Nicox Announces Approval of ZERVIATE in China
Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China, adding a royalty revenue stream for Nicox. Ocumension forecasts peak sales over $100 million annually within 7 years.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath